Menu Search
Equities

Emergent BioSolutions Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ER4:STU

Emergent BioSolutions Inc

Actions
  • Price (EUR)9.20
  • Today's Change0.322 / 3.63%
  • Shares traded300.00
  • 1 Year change-8.05%
  • Beta2.3701
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

  • Revenue in USD (TTM)788.90m
  • Net income in USD75.90m
  • Incorporated2003
  • Employees900.00
  • Location
    Emergent BioSolutions Inc300 Professional DrGAITHERSBURG 20879United StatesUSA
  • Phone+1 (240) 631-3200
  • Fax+1 (240) 631-3203
  • Websitehttps://emergentbiosolutions.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.